ARCHIVES

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

J&J, Amgen Settle Lawsuit Over ESAs As FDA Prepares Another Label Change.

July 18, 2008

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

FDA Says Medicare Policy On ESAs “Consistent With The Available Data.”

October 19, 2007

CCOP Review Completed; 72 Applications Submitted, 23 More For Minority CCOP

December 1, 1989

In Brief: Last Two NCAB Choices Named; Hellman Heads ASCO, Sartorelli Named President Of AACR

May 16, 1986

BSA Eliminates Second Review For P01 Grants; R01Payline To increase to 24th Percentile

November 23, 1997